Femasys (NASDAQ:FEMY) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Femasys (NASDAQ:FEMY) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock.

Femasys Stock Performance

FEMY stock opened at $1.29 on Friday. The stock’s 50 day simple moving average is $1.41 and its 200 day simple moving average is $1.22. Femasys has a 12-month low of $0.86 and a 12-month high of $1.84. The firm has a market cap of $29.54 million, a P/E ratio of -1.59 and a beta of -2.85. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86.

Femasys (NASDAQ:FEMY) last released its earnings results on Thursday, March 27th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The firm had revenue of $0.58 million during the quarter, compared to analyst estimates of $1.66 million. As a group, equities research analysts predict that Femasys will post -0.86 EPS for the current year.

Hedge Funds Weigh In On Femasys

A number of hedge funds and other institutional investors have recently bought and sold shares of FEMY. XTX Topco Ltd raised its position in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares during the period. Geode Capital Management LLC grew its stake in Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after buying an additional 17,473 shares during the last quarter. Virtu Financial LLC acquired a new stake in Femasys in the fourth quarter worth $25,000. Northern Trust Corp lifted its stake in Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after buying an additional 37,675 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Femasys during the fourth quarter valued at $30,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.